Skip to main content
Alison Schram, MD, Oncology, New York, NY

AlisonSchramMD

Oncology New York, NY

Fellow

Overview of Dr. Schram

Dr. Alison Schram is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center, New York-Presbyterian Hospital, and New York-Presbyterian Hospital. She received her medical degree from Perelman School of Medicine at the University of Pennsylvania and has been in practice 5 years. She is one of 497 doctors at Memorial Sloan Kettering Cancer Center and one of 375 doctors at New York-Presbyterian Hospital who specialize in Oncology. She has more than 60 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2018
  • Brigham and Women's Hospital
    Brigham and Women's HospitalResidency, Internal Medicine, 2012 - 2015
  • Perelman School of Medicine at the University of Pennsylvania
    Perelman School of Medicine at the University of PennsylvaniaClass of 2012

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2015 - 2026
  • CT State Medical License
    CT State Medical License 2023 - 2025
  • NJ State Medical License
    NJ State Medical License 2019 - 2025
  • MA State Medical License
    MA State Medical License 2014 - 2015
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Article Widespread Selection for Oncogenic Mutant Allele Imbalance in Cancer  
    Sarat Chandarlapaty, Alison M Schram, David M Hyman, David B Solit, ScienceDirect
  • Genome Doubling Shapes the Evolution and Prognosis of Advanced Cancers  
    Alison M Schram, Jose Baselga, Mark E Robson, David B Solit, Zsofia K Stadler, Nature

Lectures

  • Clinicopathologic characteristics of fusion-positive cancers: A single-institution study. 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/1/2019

Press Mentions

  • FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers with NRG1 Fusions
    FDA Approves Zenocutuzumab for Pancreatic and Lung Cancers with NRG1 FusionsDecember 5th, 2024
  • FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung Cancers
    FDA OKs First Drug Targeting NRG1 Gene Fusion in Pancreatic, Lung CancersDecember 4th, 2024
  • Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-Fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)
    Merus Presents Clinical Data on Zenocutuzumab (Zeno) in NRG1-Fusion (NRG1+) Cancer at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting (Oral Abstract)June 5th, 2022
  • Join now to see all